Development of a Smart Portable Hypoxic Chamber with Accurate Sensing, Control and Visualization of In Vitro Cell Culture for Replication of Cancer Microenvironment.
automated
cancer
drug resistance
hypoxia
remote monitoring
tumor microenvironment
visualization
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Jul 2023
16 Jul 2023
Historique:
received:
15
02
2023
revised:
09
07
2023
accepted:
12
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Clinical resistance towards treatment is a major concern in cancer therapy. This is due to in vitro studies lacking essential microenvironmental aspects. Tumor-hypoxia is an important pathophysiological phenomenon in numerous malignant tumors. Various studies have shown the importance of a hypoxic microenvironment (HME) in cancer drug resistance and its effects on cellular signaling and metabolism pathways. Most drugs fail in transition from a laboratory to clinical trials because of the variability in the testing microenvironment conditions. It is, thus, very crucial that research work needs to replicate these conditions in vitro to test the drugs and/or drug carriers for cancer therapy. Previous works have used a portable hypoxia chamber to reduce the cell microenvironment to hypoxic conditions. These techniques lack reliability and consistency due to a lack of control and visualization. In this research, we developed a smart portable hypoxia chamber that could accurately control the oxygen inside the portable chamber and have a global visualization. The proposed hypoxia chamber provided ease of use with the ranges of 1% to 20% oxygen with increments of 0.5%, as well as reproducibility and accuracy. The chamber displayed great precision on reaching the set oxygen limit and a high stability in maintaining that set level of oxygen compared to the uncontrolled setup for extended durations (24 h). For instance, at a 2% oxygen level, our automated system maintained this level over 1400 min, whereas the oxygen level fluctuated up to 4.5% in the conventional hypoxic chamber. We have also demonstrated the pitfalls of uncontrolled and non-visualized hypoxia chamber setup and the dire need for our system. The hypoxia-induced factor (HIF-1α) expression in cancer cell lines was tested and compared between the conventional hypoxia setup and our automated hypoxia chamber. We observed that there was a twofold increase in HIF-1α expression in the automated controlled chamber compared to the conventional device. The device also provided real-time sensing, visualization and control of the chamber conditions, which could aid in complex in vitro studies.
Identifiants
pubmed: 37509306
pii: cancers15143645
doi: 10.3390/cancers15143645
pmc: PMC10378062
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancer Prevention and Research Institute of Texas
ID : RP210206
Références
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304
pubmed: 34350796
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545980
J Clin Pathol. 2012 Oct;65(10):872-6
pubmed: 22569539
Cells. 2021 Mar 19;10(3):
pubmed: 33808542
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Biotechniques. 2015 Oct 01;59(4):223-4, 226, 228-9
pubmed: 26458550
Cell Biol Int. 2022 Jan;46(1):46-51
pubmed: 34658125
Hypoxia (Auckl). 2015 Sep 18;3:35-43
pubmed: 27774480
J Biol Chem. 2004 Apr 9;279(15):14871-8
pubmed: 14744852
Br J Radiol. 2014 Mar;87(1035):20130676
pubmed: 24588669
Carcinogenesis. 2012 Aug;33(8):1598-607
pubmed: 22678117
PLoS One. 2016 Feb 10;11(2):e0148923
pubmed: 26862760
J Biol Chem. 2005 Jun 10;280(23):22473-81
pubmed: 15802268
Cell Death Differ. 2008 Apr;15(4):621-7
pubmed: 18259201
Am J Cancer Res. 2014 Jan 15;4(1):53-60
pubmed: 24482738
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
PLoS One. 2022 Aug 16;17(8):e0273042
pubmed: 35972942
EMBO J. 2003 Aug 15;22(16):4082-90
pubmed: 12912907
Life Sci. 2021 Dec 1;286:120057
pubmed: 34662552
Cancer Metastasis Rev. 1994 Jun;13(2):139-68
pubmed: 7923547
Cell. 2012 Feb 3;148(3):399-408
pubmed: 22304911
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
Front Endocrinol (Lausanne). 2020 Feb 21;11:57
pubmed: 32153502
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
PLoS One. 2011;6(11):e27460
pubmed: 22132102
Radiat Oncol. 2018 Nov 13;13(1):220
pubmed: 30424810
Anticancer Res. 2018 Nov;38(11):6299-6308
pubmed: 30396950
Korean J Physiol Pharmacol. 2016 Jan;20(1):53-62
pubmed: 26807023
Mol Biol Cell. 2004 Jul;15(7):3042-52
pubmed: 15107465
PLoS One. 2020 May 21;15(5):e0233109
pubmed: 32437461
Methods Protoc. 2021 Apr 08;4(2):
pubmed: 33917811
Sci Rep. 2021 Mar 11;11(1):5777
pubmed: 33707510
Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2316-25
pubmed: 26404487
HardwareX. 2021 Dec 18;11:e00253
pubmed: 35509920